Cardium Reports Q2 Financials

Cardium Therapeutics has reported its financial results for the second quarter ended June 30, 2009. For this period, the company reported a loss from operations of $2.3m, as compared to $4.6m for the same quarter in 2008, a reduction of 48%.

Cardium has reported a decrease in the revenue to $6,996 for the second quarter of 2009, as compared to $262,430 for the same period an year ago. Net loss for the company has increased to $11.1m or $0.24 per share for the second quarter, as compared to $6.6m or $0.15 per share for Q2, 2008.

For the six month ended period, the revenue was $25,632 compared to $374,633 for the same period in 2008. Net loss for the period was $25.8m or $0.55 per share, as compared to $13.3m or $0.31 per share for the last year. The company has also reported a loss from operations of $4.8m, compared to $9.3m for the same period an year ago.